Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This observational study is following people with Depression to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
This study is comparing Psilocybin and Psilocyn with placebo for people with depression. Participants receive Psilocybin and Psilocyn or placebo and complete study visits and assessments.
This study is comparing Low Dose Psilocybin with placebo for people with depression. Participants receive Low Dose Psilocybin or placebo and complete study visits and assessments.
This study is comparing Psilocybin with Control for people with Major Depression. Participants receive Psilocybin or Control and complete study visits and assessments.
This study is comparing Psilocybin (drug) with placebo for people with Treatment Resistant Depression. Participants receive Psilocybin (drug) or placebo and complete study visits and assessments.
This study is looking at whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy for people with Parkinson Disease or Depression. Participants receive a study treatment and complete follow-up visits and assessments.
This study is looking at whether a digital support tool can help people with depression. Participants receive a study treatment and complete follow-up visits and assessments.
This study is comparing Psilocybin with placebo for people with depression or Alcohol Use Disorder. Participants receive Psilocybin or placebo and complete study visits and assessments.
This study is comparing Psilocybin with placebo for people with depression. Participants receive Psilocybin or placebo and complete study visits and assessments.
This study is looking at also assess whether psilocybin may improve quality of life in those individuals for people with Depressive Symptoms, Depression, Alzheimer Disease, or Mild Cognitive Impairment. Participants receive a study treatment and complete follow-up visits and assessments.
This study is looking at determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression for people with Treatment Resistant Depression. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
This study is comparing Psilocybin 25 mg with placebo for people with major depression. Participants receive Psilocybin 25 mg or placebo and complete study visits and assessments.